16 September 2026 editorial review · Item
Liraglutide as an adjunct in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Liraglutide as an adjunct in T1D
Scope and findings: Added in the second discovery pass. Daily GLP-1 therapy studied as an adjunct to insulin in large T1D trials. Modest HbA1c and weight benefits were accompanied by more symptomatic hypoglycemia and hyperglycemia with ketosis; T1D use is off-label. Numerical claims are tied to the cited product specifications or named study, and editorial scores do not represent measured comparative performance.
Primary sources checked:
Limits: Scope is the specific claims documented in the new record. Local stock, payer rules, every hardware variant and unreported head-to-head outcomes are not verified. Regulatory status, manufacturer marketing and clinical performance are distinct.